Mirabegron is a medication used in the management of overactive bladder. It is in the sympathomimetic class of medications. It received approval from the US Food and Drug Administration (FDA) in June 2012 for treating overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. This activity reviews the indications, action, and contraindications for mirabegron as a valuable agent in the management of overactive bladder, including the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the care of patients with overactive bladder and related conditions.

**Objectives:**
- Identify the mechanism of action of mirabegron.
- Review the indications for initiating therapy with mirabegron.
- Outline the possible adverse effects associated with mirabegron.
- Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who can benefit from mirabegron therapy.